Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 7/1, from 8 a.m. to 6 p.m. and 7/2, from 8 a.m. to 4:30 p.m. at the Hilton Washington DC/Silver Spring, The Ballroom, 8727 Colesville Rd, Silver Spring, MD. On both days, the committee will discuss the role of cardiovascular assessment in the preapproval and postapproval settings for drugs and biologics developed for the treatment of Type 2 diabetes mellitus. Contact Paul Tran, (301) 827- 7001. To view this notice, click here.